Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.56 |
| ▸ | MAPT | P10636 | 7/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | ACP1 | P24666 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ACACA | Q13085 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16097509 | 0.89 | SMN1; SMN2 (0.57) | HPGDSMN1; SMN2LMNAALDH1A1MAPT | |
| SCHEMBL16098736 | 0.87 | LMNA (0.56) | HPGDSMN1; SMN2LMNAALDH1A1MAPT | |
| SCHEMBL16098101 | 0.86 | KDM4E (0.77) | HPGDSMN1; SMN2LMNAALDH1A1MAPT | |
| SCHEMBL6754682 | 0.84 | KDM4E (0.55) | HPGDSMN1; SMN2LMNAALDH1A1MAPT | |
| SCHEMBL16096770 | 0.83 | HPGD (0.51) | HPGDSMN1; SMN2LMNAALDH1A1MAPT | |
| SCHEMBL16098942 | 0.80 | HPGD (0.47) | HPGDSMN1; SMN2LMNAALDH1A1MAPT | |
| SCHEMBL6534330 | 0.77 | ALDH1A1 (0.60) | HPGDSMN1; SMN2LMNAALDH1A1MAPT | |
| SCHEMBL16098548 | 0.77 | MEN1 (0.52) | HPGDSMN1; SMN2LMNAALDH1A1MAPT | |
| SCHEMBL7920082 | 0.77 | KDM4E (0.78) | HPGDSMN1; SMN2LMNAALDH1A1MAPT | |
| SCHEMBL26456461 | 0.77 | ALDH1A1 (0.64) | HPGDSMN1; SMN2LMNAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10179770-B2 | Quinolines derivatives as novel anticancer agents | GENOSCIENCE PHARMA (FR) | 2019-01-15 | — | — | US | disclosed |
| US-10179770-B2 | Quinolines derivatives as novel anticancer agents | GENOSCIENCE PHARMA (FR) | 2019-01-15 | — | — | US | disclosed |
| CN-105102442-B | Quinoline as anticarcinogen | 基因科学医药公司 | 2018-11-09 | — | — | CN | disclosed |
| EP-2976333-B1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | GENOSCIENCE PHARMA SAS (FR) | 2018-08-08 | — | — | EP | disclosed |
| EP-2976333-B1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | GENOSCIENCE PHARMA SAS (FR) | 2018-08-08 | — | — | EP | disclosed |
| US-20160280653-A1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | GENOSCIENCE PHARMA (FR) | 2016-09-29 | — | — | US | disclosed |
| US-20160280653-A1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | GENOSCIENCE PHARMA (FR) | 2016-09-29 | — | — | US | disclosed |
| US-20160280653-A1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | GENOSCIENCE PHARMA (FR) | 2016-09-29 | — | — | US | disclosed |
| EP-2976333-A1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | Genoscience Pharma SAS (FR) | 2016-01-27 | — | — | EP | disclosed |
| CN-105102442-A | Quinolines derivatives as novel anticancer agents | GENOSCIENCE PHARMA | 2015-11-25 | — | — | CN | disclosed |
| WO-2014147611-A1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | GENOSCIENCE PHARMA (FR) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014147611-A1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | GENOSCIENCE PHARMA (FR) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10179770-B2 | Quinolines derivatives as novel anticancer agents | NQO2, MKI67, NQO1 | HPGD 630/4885SMN1; SMN2 3931/4885LMNA 2412/4885 |
| US-20160280653-A1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | NQO2, MKI67, NQO1 | HPGD 630/4885SMN1; SMN2 3931/4885LMNA 2412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.